UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with moderate-to-severe plaque psoriasis treated with BIMZELX® (bimekizumab-bkzx), an ...

UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ...

Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

Biopharmaceutical company UCB has received US Food and Drug Administration (FDA) approval for BIMZELX (bimekizumab-bkzx) to ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

Belgian drugmaker UCB (Euronext: UCB) has announced the presentation of new four-year data in patients with moderate to ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

Bimzelx was first approved last year for the treatment of moderate to severe psoriasis in adults, making it the first and ...

Dice’s lead product candidate is oral IL-17 inhibitor DC-806, which is in phase 2 testing as a treatment for plaque psoriasis ... (brodalumab), and UCB’s Bimzelx (bimekizumab).

1) Bimekizumab: UCB's first-in-class dual IL-17 A/F inhibitor was approved in the EU last year as Bimzelx but turned ... for moderate to severe plaque psoriasis therapies thanks to superior ...

Discover Evotec SE's groundbreaking patent for ENaC-inhibiting compounds, offering innovative treatments for respiratory, skin, and ocular diseases. Explore their potential!